Satellos Bioscience Inc.
MSCLF
$0.483
-$0.037-7.12%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 14.31M | 12.99M | 12.64M | 10.24M | 6.53M |
| Gross Profit | -14.31M | -12.99M | -12.64M | -10.24M | -6.53M |
| SG&A Expenses | 5.99M | 6.31M | 6.30M | 6.10M | 4.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.30M | 19.31M | 18.94M | 16.34M | 11.45M |
| Operating Income | -20.30M | -19.31M | -18.94M | -16.34M | -11.45M |
| Income Before Tax | -20.53M | -20.97M | -17.00M | -15.66M | -11.76M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.53 | -20.97 | -17.00 | -15.66 | -11.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.53M | -20.97M | -17.00M | -15.66M | -11.76M |
| EBIT | -20.30M | -19.31M | -18.94M | -16.34M | -11.45M |
| EBITDA | -20.28M | -19.30M | -18.94M | -16.33M | -11.44M |
| EPS Basic | -0.18 | -0.19 | -0.15 | -0.15 | -0.13 |
| Normalized Basic EPS | -0.10 | -0.10 | -0.09 | -0.09 | -0.08 |
| EPS Diluted | -0.18 | -0.19 | -0.15 | -0.15 | -0.13 |
| Normalized Diluted EPS | -0.10 | -0.10 | -0.09 | -0.09 | -0.08 |
| Average Basic Shares Outstanding | 459.11M | 451.41M | 451.17M | 416.55M | 345.62M |
| Average Diluted Shares Outstanding | 459.11M | 451.41M | 451.17M | 416.55M | 345.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
